What is Arena Pharmaceuticals Book Value per Share?
Arena Pharmaceuticals's book value per share for the quarter that ended in Dec. 2021 was $10.94.
During the past 12 months, Arena Pharmaceuticals's average Book Value Per Share Growth Rate was -40.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -3.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 48.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 29.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Arena Pharmaceuticals was 135.30% per year. The lowest was -64.30% per year. And the median was -13.90% per year.
During the past 13 years, the highest P/B Ratio of Arena Pharmaceuticals was 135.77. The lowest was 1.72. And the median was 7.87.
Arena Pharmaceuticals Book Value per Share Historical Data
The historical data trend for Arena Pharmaceuticals's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Arena Pharmaceuticals's Book Value per Share
For the Biotechnology subindustry, Arena Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arena Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Arena Pharmaceuticals's PB Ratio falls into.
Arena Pharmaceuticals Book Value per Share Calculation
Arena Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2021 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Arena Pharmaceuticals (NAS:ARNA) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Arena Pharmaceuticals Book Value per Share Related Terms
Thank you for viewing the detailed overview of Arena Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Arena Pharmaceuticals (Arena Pharmaceuticals) Business Description
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARNA has been successfully added to your 